CN110167557A - 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法 - Google Patents

用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法 Download PDF

Info

Publication number
CN110167557A
CN110167557A CN201780078133.2A CN201780078133A CN110167557A CN 110167557 A CN110167557 A CN 110167557A CN 201780078133 A CN201780078133 A CN 201780078133A CN 110167557 A CN110167557 A CN 110167557A
Authority
CN
China
Prior art keywords
compound
application
subject
test
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078133.2A
Other languages
English (en)
Chinese (zh)
Inventor
丽贝卡·陶布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of CN110167557A publication Critical patent/CN110167557A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780078133.2A 2016-10-18 2017-10-18 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法 Pending CN110167557A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662409833P 2016-10-18 2016-10-18
US62/409,833 2016-10-18
US201762516594P 2017-06-07 2017-06-07
US62/516,594 2017-06-07
PCT/US2017/057203 WO2018075650A1 (en) 2016-10-18 2017-10-18 Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Publications (1)

Publication Number Publication Date
CN110167557A true CN110167557A (zh) 2019-08-23

Family

ID=60480362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078133.2A Pending CN110167557A (zh) 2016-10-18 2017-10-18 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法

Country Status (12)

Country Link
US (3) US11090308B2 (https=)
EP (2) EP3528817B1 (https=)
JP (3) JP2019533019A (https=)
KR (2) KR20230156159A (https=)
CN (1) CN110167557A (https=)
AU (1) AU2017346871B2 (https=)
CA (1) CA3040888A1 (https=)
DK (1) DK3528817T3 (https=)
ES (1) ES2924257T3 (https=)
IL (2) IL302336B2 (https=)
MX (1) MX394463B (https=)
WO (1) WO2018075650A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111562321A (zh) * 2020-04-16 2020-08-21 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113474335A (zh) * 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
WO2022052822A1 (zh) * 2020-09-10 2022-03-17 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
CN114375193A (zh) * 2019-09-12 2022-04-19 拓臻制药公司 甲状腺激素受体β激动剂化合物
TWI763147B (zh) * 2019-11-26 2022-05-01 大陸商昆藥集團股份有限公司 1，2，4-三嗪-3，5-二酮類化合物及其製備方法和應用
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
US12338232B2 (en) 2018-12-13 2025-06-24 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN121648128A (zh) * 2026-02-03 2026-03-13 华中科技大学同济医学院附属同济医院 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
WO2018075650A1 (en) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
PT3911647T (pt) * 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
EP4204419A1 (en) 2020-10-19 2023-07-05 Teva Pharmaceuticals International GmbH Solid state forms of resmetirom
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
US20250000836A1 (en) * 2021-07-21 2025-01-02 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
PE20241327A1 (es) * 2021-11-11 2024-06-26 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-beta
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2024263714A1 (en) * 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801960A (zh) * 2007-09-20 2010-08-11 霍夫曼-拉罗奇有限公司 甲状腺激素类似物的前药
CN105008335A (zh) * 2012-09-17 2015-10-28 马德里加尔制药公司 合成甲状腺激素类似物及其多形体的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
HRP20100611T1 (hr) 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
CN106132969A (zh) * 2014-02-14 2016-11-16 森普拉制药公司 用于治疗糖尿病和肝病的组合物和方法
WO2018075650A1 (en) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
AR115666A1 (es) 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801960A (zh) * 2007-09-20 2010-08-11 霍夫曼-拉罗奇有限公司 甲状腺激素类似物的前药
CN105008335A (zh) * 2012-09-17 2015-10-28 马德里加尔制药公司 合成甲状腺激素类似物及其多形体的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTHA J. KELLY等: ""Discovery of 2‑[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment"", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
REBECCA TAUB等: ""Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-b agonist"", 《ATHEROSCLEROSIS》 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338232B2 (en) 2018-12-13 2025-06-24 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US12459926B2 (en) 2018-12-13 2025-11-04 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US12365669B2 (en) 2018-12-13 2025-07-22 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
CN113474335A (zh) * 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193A (zh) * 2019-09-12 2022-04-19 拓臻制药公司 甲状腺激素受体β激动剂化合物
CN114375193B (zh) * 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
TWI763147B (zh) * 2019-11-26 2022-05-01 大陸商昆藥集團股份有限公司 1，2，4-三嗪-3，5-二酮類化合物及其製備方法和應用
CN111562321A (zh) * 2020-04-16 2020-08-21 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
CN116171275A (zh) * 2020-09-10 2023-05-26 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
WO2022052822A1 (zh) * 2020-09-10 2022-03-17 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
US12595254B2 (en) 2020-09-10 2026-04-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Resmetirom, preparation method therefor, and use thereof
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN121648128A (zh) * 2026-02-03 2026-03-13 华中科技大学同济医学院附属同济医院 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Also Published As

Publication number Publication date
IL302336A (en) 2023-06-01
MX394463B (es) 2025-03-19
JP2025122012A (ja) 2025-08-20
AU2017346871B2 (en) 2023-08-03
CA3040888A1 (en) 2018-04-26
JP2024001055A (ja) 2024-01-09
DK3528817T3 (da) 2022-08-08
IL266054A (en) 2019-06-30
EP4112056A1 (en) 2023-01-04
AU2017346871A1 (en) 2019-05-02
EP3528817A1 (en) 2019-08-28
IL266054B2 (en) 2023-10-01
MX2019004492A (es) 2019-11-18
US20210330675A1 (en) 2021-10-28
KR20230156159A (ko) 2023-11-13
IL302336B1 (en) 2025-07-01
JP2019533019A (ja) 2019-11-14
ES2924257T3 (es) 2022-10-05
IL302336B2 (en) 2025-11-01
US11090308B2 (en) 2021-08-17
EP4112056B1 (en) 2026-01-21
US20240156826A1 (en) 2024-05-16
KR20190109387A (ko) 2019-09-25
WO2018075650A1 (en) 2018-04-26
IL266054B1 (en) 2023-06-01
US20200230146A1 (en) 2020-07-23
US11806353B2 (en) 2023-11-07
EP3528817B1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
US11806353B2 (en) Methods of treating liver disorders or lipid disorders with a THR-beta agonist
US10717735B2 (en) Solid forms of a compound for modulating kinases
US20200339591A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
KR102014875B1 (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
JP2019533019A5 (https=)
EA019571B1 (ru) Применение сульфизоксазола для лечения болезни альцгеймера
HK1208823A1 (en) Modulation of hepatitis b virus cccdna transcription
EA034869B1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
US10676747B2 (en) Methods for improving cognitive function via modulation of quinone reductase 2
CN116271033B (zh) 一种以sqle基因或蛋白为靶点治疗克唑替尼肝脏毒性的药物
CN117320701A (zh) 一种降低肝脏中甘油三酯合成的方法
CN119345327A (zh) 双受体激动剂在结直肠癌治疗中的用途
HK40016954A (en) Combinations of akt and mek inhibitor compounds, and methods of use
Ting Pharmacokinetics and limited sampling strategies of mycophenolic acid in lung transplant recipients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190823